185 related articles for article (PubMed ID: 37096557)
1. Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma.
Peng X; Yu Z; Surineni G; Deng B; Zhang M; Li C; Sun Z; Pan W; Liu Y; Liu S; Yu B; Chen J
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2201408. PubMed ID: 37096557
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma.
Peng X; Li L; Chen J; Ren Y; Liu J; Yu Z; Cao H; Chen J
J Med Chem; 2022 Feb; 65(3):2434-2457. PubMed ID: 35043615
[TBL] [Abstract][Full Text] [Related]
3. Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
Xu X; Zhang D; Zhao T; Wang M; Li Y; Du Q; Kou J; Li Z; Bian J
Eur J Med Chem; 2022 Apr; 233():114228. PubMed ID: 35245830
[TBL] [Abstract][Full Text] [Related]
4. Groebke Blackburn Bienaymé-mediated multi-component synthesis of selective HDAC6 inhibitors with anti-inflammatory properties.
Kraft FB; Enns J; Honin I; Engelhardt J; Schöler A; Smith ST; Meiler J; Schäker-Hübner L; Weindl G; Hansen FK
Bioorg Chem; 2024 Feb; 143():107072. PubMed ID: 38185013
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
Liang T; Xue J; Yao Z; Ye Y; Yang X; Hou X; Fang H
Eur J Med Chem; 2021 Oct; 221():113526. PubMed ID: 33992929
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
Zhang XH; Kang HQ; Tao YY; Li YH; Zhao JR; Ya-Gao ; Ma LY; Liu HM
Eur J Med Chem; 2021 Jun; 218():113392. PubMed ID: 33831778
[TBL] [Abstract][Full Text] [Related]
8. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
9. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models.
Depetter Y; Geurs S; De Vreese R; Goethals S; Vandoorn E; Laevens A; Steenbrugge J; Meyer E; de Tullio P; Bracke M; D'hooghe M; De Wever O
Int J Cancer; 2019 Aug; 145(3):735-747. PubMed ID: 30694564
[TBL] [Abstract][Full Text] [Related]
10. Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.
Li Y; Quan J; Song H; Li D; Ma E; Wang Y; Ma C
Bioorg Chem; 2021 Sep; 114():105081. PubMed ID: 34153811
[TBL] [Abstract][Full Text] [Related]
11. Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects.
Vishwakarma S; Iyer LR; Muley M; Singh PK; Shastry A; Saxena A; Kulathingal J; Vijaykanth G; Raghul J; Rajesh N; Rathinasamy S; Kachhadia V; Kilambi N; Rajgopal S; Balasubramanian G; Narayanan S
Int Immunopharmacol; 2013 May; 16(1):72-8. PubMed ID: 23541634
[TBL] [Abstract][Full Text] [Related]
12. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
Eur J Med Chem; 2020 Mar; 190():112086. PubMed ID: 32058238
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
[TBL] [Abstract][Full Text] [Related]
14. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
Wang F; Zhong BW; Zhao ZR
J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
[TBL] [Abstract][Full Text] [Related]
15. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Biological Evaluation of Novel Quinazolin-4(3H)-One-Based Histone Deacetylase 6 (HDAC6) Inhibitors for Anticancer Activity.
Khetmalis YM; Fathima A; Schweipert M; Debarnot C; Bandaru NVMR; Murugesan S; Jamma T; Meyer-Almes FJ; Sekhar KVGC
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446224
[TBL] [Abstract][Full Text] [Related]
18. Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction.
Sharma C; Oh YJ; Park B; Lee S; Jeong CH; Lee S; Seo JH; Seo YH
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835389
[TBL] [Abstract][Full Text] [Related]
19. Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents.
Peng X; Chen J; Li L; Sun Z; Liu J; Ren Y; Huang J; Chen J
J Med Chem; 2021 Jun; 64(12):8447-8473. PubMed ID: 34097389
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects.
Peng X; Ren Y; Pan W; Liu J; Chen J
J Med Chem; 2023 Jan; 66(1):627-640. PubMed ID: 36516438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
